Segall Bryant & Hamill’s DexCom DXCM Stock Holding History

Segall Bryant & Hamill’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,450	Closed	-$957K	–	564
2023 Q2	$957K	Buy	7,450 +270	+4%	+$32.7K	0.01%	489
2023 Q1	$834K	Sell	7,180 -300	-4%	-$33.6K	0.01%	510
2022 Q4	$847K	Sell	7,480 -300	-4%	-$32.9K	0.01%	512
2022 Q3	$627K	Sell	7,780 -840	-10%	-$71.1K	0.01%	544
2022 Q2	$643K	Sell	8,620 -160	-2%	-$14.6K	0.01%	548
2022 Q1	$1.12M	Hold	8,780	–	–	0.01%	502
2021 Q4	$1.18M	Hold	8,780	–	–	0.01%	443
2021 Q3	$1.2M	Hold	8,780	–	–	0.01%	507
2021 Q2	$936K	Sell	8,780 -99,328	-92%	-$9.54M	0.01%	529
2021 Q1	$9.71M	Buy	108,108 +99,328	+1,131%	+$9.32M	0.1%	223
2020 Q4	$811K	Buy	8,780 +640	+8%	+$57.1K	0.01%	500
2020 Q3	$839K	Buy	8,140 +940	+13%	+$98.2K	0.01%	478
2020 Q2	$730K	Hold	7,200	–	–	0.01%	507
2020 Q1	$485K	Hold	7,200	–	–	0.01%	598
2019 Q4	$394K	Sell	7,200 -1,880	-21%	-$89.2K	0.01%	690
2019 Q3	$339K	Hold	9,080	–	–	0.01%	713
2019 Q2	$340K	Buy	+9,080	New	+$285K	0.01%	722

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Segall Bryant & Hamill's DXCM Position: Q3 2023 in Review

Segall Bryant & Hamill sold out of DexCom (DXCM) in Q3 2023, closing a stake of 7,450 shares — an estimated $957K sold.

Segall Bryant & Hamill first reported a position in DXCM in Q2 2019 and held it in 17 quarters. The position peaked at $9.71M in Q1 2021. 902 funds tracked by Wall St. Rank hold DXCM as of Q3 2023.

Segall Bryant & Hamill reported no remaining DexCom position as of Q3 2023 after selling out during the quarter.
Segall Bryant & Hamill sold 7,450 DexCom shares in Q3 2023, an estimated $957K.
Segall Bryant & Hamill first reported a position in DexCom in Q2 2019 and held it in 17 quarters.
Segall Bryant & Hamill's DexCom position peaked at $9.71M in Q1 2021.
902 funds tracked by Wall St. Rank held DexCom as of Q3 2023.

Based on Segall Bryant & Hamill's 13F filing for Q3 2023, filed 9 Nov 2023.